SCHEMBL6790961

SCHEMBL6790961

NC(=O)c1ccncc1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ UMPS P11172 1/20 0.44
▸ LMNA P02545 3/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ GLA P06280 1/20 0.39
▸ EIF4E P06730 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ TOP1 P11387 1/20 0.39
▸ ADORA1 P30542 1/20 0.39
▸ THPO P40225 1/20 0.39
▸ PMP22 Q01453 1/20 0.39
▸ PYGL P06737 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27588394 1.00 UMPS (0.44) UMPSLMNASMN1; SMN2ALDH1A1TSHR
SCHEMBL6784339 1.00 UMPS (0.44) UMPSLMNASMN1; SMN2ALDH1A1TSHR
SCHEMBL27606205 1.00 UMPS (0.44) UMPSLMNASMN1; SMN2ALDH1A1TSHR
SCHEMBL5878336 0.90 UMPS (0.44) UMPSLMNASMN1; SMN2ALDH1A1TSHR
SCHEMBL6796400 0.84 KDM4E (0.45) ALDH1A1GLAKDM4EGAASLC5A2
SCHEMBL6932964 0.84 KDM4E (0.45) ALDH1A1GLAKDM4EGAASLC5A2
SCHEMBL8973945 0.81 PYGL (0.43) PYGLSLC5A2
SCHEMBL15968709 0.81 SLC5A2 (0.46) UMPSPYGLSLC5A2
Ribose (Furanose) SCHEMBL17479515 0.78 TDP1 (0.47) UMPSLMNASMN1; SMN2ALDH1A1TSHR
SCHEMBL6789543 0.78 PYGL (0.41) PYGLMAPTSLC5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040266723-A1 Antiviral agents for treatment of Flaviviridae infections PHARMASSET, INC. 2004-12-30 — — US disclosed
EP-1366055-A2 ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS Pharmasset Limited (BB) 2003-12-03 — — EP disclosed
WO-2002048165-A2 ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS PHARMASSET LTD. (BB) 2002-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266723-A1 Antiviral agents for treatment of Flaviviridae infections HAVCR2, MAVS, EIF2AK2 UMPS 454/4885LMNA 4363/4885SMN1; SMN2 1046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback